Esophageal cancer medical therapy

Esophageal cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Esophageal cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Esophageal cancer medical therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Esophageal cancer medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Esophageal cancer medical therapy
CDC on Esophageal cancer medical therapy
Esophageal cancer medical therapy in the news
Blogs on Esophageal cancer medical therapy
Directions to Hospitals Treating Esophageal cancer
Risk calculators and risk factors for Esophageal cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

Chemotherapy is used to treat advanced esophageal cancer. Chemotherapy can be used alone as monotherapy or in combination with radiotherapy or surgery. Chemotherapy may be used as a neoadjuvant therapy after surgery to kill any cancerous cells that may have been left, or as an adjuvant therapy to shrink a tumor before being surgically resected, and finally, in advanced tumors to shrink them or to relieve symptoms.

Medical Therapy

• Some common drugs and drug combinations used to treat advanced esophageal cancer include:
  • Carboplatin and paclitaxel
    • Combined with radiation
  • Cisplatin and 5-fluorouracil (5-FU)
    • Combined with radiation
  • ECF: epirubicin, cisplatin, and 5-FU
    • Especially for gastroesophageal junction tumors
  • DCF: docetaxel, cisplatin, and 5-FU
  • Cisplatin with capecitabine
  • Oxaliplatin and either 5-FU or capecitabine
  • Irinotecan
  • For some esophagus cancers that are HER-2 positive, chemo may be used along with the targeted drug trastuzumab or ramucirumab.

Esophageal cancer

• 1 Stage IV Non - Her 2 positive Esophageal Cancer
  • 1.1 Advanced esophageal cancer
    • 1.1.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): 21 day cycle of docetaxel 75mg/m2 IV on day 1, cisplatin 75mg/m2 IV on day 1 and fluorouracil 750mg/m2 IV q24h from day 1 through day 5
        • Alternative regimen (1): 14 day cycle of modified docetaxel 40mg/m2 IV on day 1, leucovorin 400mg/m2 IV on day 1, fluorouracil 400mg/m2 bolus on day 1, fluorouracil 2000mg/m2 IV on day 1, cisplatin 40mg/m2 IV on day 3
        • Alternative regimen (2): 21 day cycle of epirubicin 50 mg/m2 IV on day 1, cisplatin 60 mg/m2 IV on day 1, fluorouracil 200 mg/m2 q24h IV for up to 6 months
        • Alternative regimen (3): 21 day cycle of epirubicin 50 mg/m2 IV on day 1, cisplatin 60 mg/m2 IV on day 1, fluorouracil 625 mg/m2 q24h PO on day 1 through day 21
        • Alternative regimen (4): 21 day cycle of epirubicin 50 mg/m2 IV on day 1, oxaliplatin 130 mg/m2 IV on day 1, cepacitabine 625 mg/m2 q24h PO on day 1 through day 21
        • Alternative regimen (5): 42 day cycle of cisplatin 30 mg/m2 IV and irinotecan 65mg/m2 IV on days 1, 8, 15, and 22
        • Alternative regimen (6): 21 day cycle of oxaliplatin 130mg/m2 IV on day 1, cepacitabine 1000mg/m2 q24h PO on day 1 through day 14

    Note (1): Treatment is continued until disease progression, unacceptable toxicity or patient withdrawal

• 2 Stage IV Her 2 positive Esophageal Cancer
  • 2.1 Advanced esophageal cancer
    • 2.1.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): 21 day cycle for 6 cycles; cisplatin 80 mg/m2 IV on day 1, cepacitabine 1000mg/m2 q24h PO on day 1 through day 14, trastuzumab 8mg/kg IV loading dose on day 1 for cycle 1 only, followed by 6mg/kg IV on day 1 of every subsequent cycle starting with cycle 2
        • Alternative regimen (1):21 day cycle for 6 cycles; cisplatin 80 mg/m2 IV on day 1, fluorouracil 800mg/m2 q24h IV on day 1 through day 5, trastuzumab 8mg/kg IV loading dose on day 1 for cycle 1 only, followed by 6mg/kg IV on day 1 of every subsequent cycle starting with cycle 2
• 3 Weekly Carboplatin and Paclitaxel with concurrent Radiotherapy
  • 3.1 Advanced esophageal cancer and esophagogastric junction cancer
    • 3.1.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): Paclitaxel 50mg/m2 IV and carboplatin AUC 2mg/ml x min IV on day 1, 8, 15, 22 and 29

    Note (1): Given weekly for 5 weeks with concurrent radiotherapy followed by surgery

    • • • Alternative regimen (1): Cisplatin 100 mg/m2 IV on day 1 through 29, fluorouracil 1000 mg/m2 q24h IV on day 1 through 4 and days 29 through 32 and radiotherapy 50.4 Gy

    Note (2): 1.8 Gy for 5 days a week (final 5.4 Gy is given as a boost) on day 1 through 5, day 8 through 12, day 15 through 19, day 22 through 29. day 22 through 26, day 29 through 33, day 36 through 38

    Note (3): Two courses of cisplatin and fluorouracil are given on days 1 and 29 of a 5.5 week course of radiotherapy

    Note (4): Trimodality therapy with cisplatin and fluorouracil with concurrent radiotherapy followed by surgery

References

Template:WikiDoc Sources